A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients With Advanced Recurrent or Metastatic Thymic Tumors
Latest Information Update: 21 Oct 2024
At a glance
- Drugs KC 1036 (Primary)
- Indications Malignant thymoma; Thymoma
- Focus Therapeutic Use
Most Recent Events
- 07 Mar 2023 Status changed from not yet recruiting to recruiting.
- 17 Jan 2023 New trial record